Literature DB >> 30116949

Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging.

Jvan Casarin1,2, Francesco Multinu1,3, Kalyan Pasupathy4, Amy Weaver1, Michaela McGree1, Lucia Tortorella1, Diogo Torres1, Amanika Kumar1, Carrie Langstraat1, Yajue Huang5, Fabio Ghezzi2, Andrea Mariani1, Gretchen Glaser6.   

Abstract

OBJECTIVE: The aim of this study was to assess the role of frozen section (FS) in identifying an absence of lymph nodes during sentinel lymph node (SLN) biopsy for apparent early-stage endometrial cancer (EC).
METHODS: Consecutive apparent early-stage EC patients who had SLNs removed after cervical injection with indocyanine green (ICG) from 1 June 2014 to 30 June 2016 were analyzed. An empty node (EN) was defined as an SLN specimen without evidence of lymph node(s). The association of tumor and patient characteristics with an EN was evaluated, and trend analysis to compare the rate of ENs over calendar quarters was performed. A decision-tree model was then created to compare the use of FS versus no FS for SLN evaluation in the hypothetical cohort affected by early-stage EC in the US each year.
RESULTS: Over the study period, 300 patients met the inclusion criteria. FS revealed ENs in 24 (8%) patients. No association between patient demographic characteristics (age, body mass index, prior abdominopelvic surgery, international federation of gynecology and obstetrics (FIGO) stage, histology, myometrial invasion, cervical stromal invasion) and presence of ENs was observed. The rate of ENs at FS did not change over time (p = 0.68). The hypothetical analysis showed a 4.3% decrease of inappropriately staged patients with the use of FS on the SLN (95% confidence interval 4.1-4.5).
CONCLUSIONS: ENs during SLN biopsy for EC staging is not a rare event and can be easily detected with FS. The implementation of FS of SLN might reduce inadequate staging of EC. Individual institutions may want to examine their own EN rates and determine if this would assist them in their SLN practices for EC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30116949     DOI: 10.1245/s10434-018-6698-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.

Authors:  Francesco Multinu; Jvan Casarin; Serena Cappuccio; Gary L Keeney; Gretchen E Glaser; William A Cliby; Amy L Weaver; Michaela E McGree; Stefano Angioni; Gavino Faa; Mario M Leitao; Nadeem R Abu-Rustum; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2019-05-22       Impact factor: 5.482

2.  Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm.

Authors:  Francesco Multinu; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Brooke A Schlappe; William A Cliby; Gretchen E Glaser; Tommaso Grassi; Gary L Keeney; Amy L Weaver; Nadeem R Abu-Rustum; Mario M Leitao; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2019-10-08       Impact factor: 5.482

3.  Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study.

Authors:  Long Yuan; Xiaowei Qi; Yi Zhang; Xinhua Yang; Fan Zhang; Linjun Fan; Li Chen; Kongyong Zhang; Ling Zhong; Yanling Li; Sijie Gan; Wenying Fu; Jun Jiang
Journal:  Cancer Biol Med       Date:  2018-11       Impact factor: 4.248

Review 4.  Lymph node evaluation in endometrial cancer: how did it change over the last two decades?

Authors:  Ciro Pinelli; Valeria Artuso; Giorgio Bogani; Antonio Simone Laganà; Fabio Ghezzi; Jvan Casarin
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.